Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: A pilot study

Cancer Imaging

Volumn 13, Issue 1, 2013, Pages 53-62

  De Paepe, Katja ^a   Bevernage, Charlotte ^a   De Keyzer, Frederik ^a   Wolter, Pascal ^a   Gheysens, Olivier ^a   Janssens, Ann ^a   Oyen, Raymond ^a   Verhoef, Gregor ^a   Vandecaveye, Vincent ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE; LACTATE DEHYDROGENASE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; NONHODGKIN LYMPHOMA; PILOT STUDY; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; WHOLE BODY MRI;

DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; LYMPHOMA, NON-HODGKIN; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 84875545345     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2013.0006     Document Type: Article

References (33)

1. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010; 60: 393-408. PMid:21030533.
2. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586. doi:10.1200/JCO.2006.09. 2403. PMid:17242396. (Pubitemid 350002966)
3. Safar V, Dupuis J, Jardin F, et al. Interim fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 2012 30 184-190 doi:10.1200/JCO.2011.38.2648. PMid 22162590.
4. Mikhaeel NG. Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now? Leuk Lymphoma 2009; 50: 1931-1936. doi:10.3109/10428190903275610. PMid:20001245.
5. Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 2011; 52: 386-392. doi:10.2967/jnumed.110.082586. PMid:21321279.
6. Chan SC, Wang HM, Yen TC, et al. (18)F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/ hypopharyngeal carcinoma: a comparative study. Eur J Nucl Med Mol Imaging 2011; 38: 1607-1619. doi:10.1007/ s00259-011-1824-y. PMid:21567252.
7. Di Cesare E, Cerone G, Enrici RM, Tombolini V, Anselmo P, Masciocchi C. MRI characterization of residual mediastinal masses in Hodgkin-s disease: long-term follow-up. Magn Reson Imaging 2004; 22: 31-38. doi:10.1016/j.mri.2003. 08.002. PMid:14972392. (Pubitemid 38221581)
8. Rahmouni A, Tempany C, Jones R, Mann R, Yang A, Zerhouni E. Lymphoma: monitoring tumor size and signal intensity with MR imaging. Radiology 1993; 188: 445-451. PMid:8327695. (Pubitemid 23216269)
9. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007; 188: 1622-1635. doi:10.2214/AJR.06.1403. PMid:17515386. (Pubitemid 46866868)
10. Thoeny HC, Ross BD. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010; 32: 2-16. doi:10.1002/jmri.22167. PMid:20575076.
11. Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 2011; 197: W384-391. doi:10.2214/AJR.10.5692. PMid:21862763.
12. Vandecaveye V, De Keyzer F, Nuyts S, et al. Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys 2007; 67: 960-971. doi:10.1016/j.ijrobp.2006.09.020. PMid:17141979.
13. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004; 22: 275-282. PMid:15468951. (Pubitemid 39264807)
14. Kwee TC, Takahara T, Ochiai R, et al. Complementary roles of whole-body diffusion-weighted MRI and 18F-FDG PET: the state of the art and potential applications. J Nucl Med 2010; 51: 1549-1558. doi:10.2967/jnumed.109.073908. PMid:20847177.
15. Murtz P, Krautmacher C, Traber F, Gieseke J, Schild HH, Willinek WA. Diffusion-weighted whole-body MR imaging with background body signal suppression: a feasibility study at 3.0 Tesla. Eur Radiol 2007; 17: 3031-3037. (Pubitemid 350142327)
16. Lin C, Itti E, Luciani A, et al. Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study. Invest Radiol 2011; 46: 341-349. PMid:21263330.
17. Wu X, Kellokumpu-Lehtinen PL, Pertovaara H, et al. Diffusionweighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma - a pilot study: comparison with 2-deoxy-2-fluoro-D-glucose-positron emission tomography/ computed tomography. NMR Biomed 2011; 24: 1181-1190. doi:10.1002/nbm.1689. PMid:21387451.
18. Murtz P, Kaschner M, Traber F, et al. Evaluation of dual-source parallel RF excitation for diffusion-weighted whole-body MR imaging with background body signal suppression at 3.0T. Eur J Radiol 2011; 81: 3614-3623.
19. Vandecaveye V, Dirix P, De Keyzer F, et al. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol 2010; 20: 1703-1714. doi:10.1007/s00330-010-1734-6. PMid:20179939.
20. Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995; 25: 60-71. PMid:7716559.
21. Vose JM, Bierman PJ, Anderson JR, et al. Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non- Hodgkin-s lymphoma. J Clin Oncol 1996; 14: 2473-2479. PMid:8823325. (Pubitemid 26300113)
22. Afaq A, Andreou A, Koh DM. Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how? Cancer Imaging 2010; 10: S179-188. doi:10.1102/1470- 7330.2010.9032. PMid:20880779.
23. Arlinghaus LR, Li X, Levy M, et al. Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy. J Oncol 2010; 919620; doi:10.1155/2010/919620. PMid:20953332.
24. Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion- weighted and contrast-enhanced MR imaging data. Radiology 2011; 260: 752-761. doi:10.1148/radiol.11102330. PMid:21771960.
25. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248: 894-900. doi:10.1148/radiol.2483071407. PMid:18710982.
26. Hayashida Y, Yakushiji T, Awai K, et al. Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol 2006; 16: 2637-2643. doi:10.1007/ s00330-006-0342-y. PMid:16909220. (Pubitemid 44823917)
27. Moffat BA, Chenevert TL, Meyer CR, et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006; 8: 259-267. doi:10.1593/neo.05844. PMid:16756718.
28. Patterson DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI-a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 2008; 5: 220-233. doi:10.1038/ncponc1073. PMid:18301415. (Pubitemid 351493681)
29. Huang MQ, Pickup S, Nelson DS, et al. Monitoring response to chemotherapy of non-Hodgkin-s lymphoma xenografts by T(2)- weighted and diffusion-weighted MRI. NMR Biomed 2008; 21: 1021-1029. doi:10.1002/nbm.1261. PMid:18988250.
30. Wu X, Korkola P, Pertovaara H, Eskola H, Jarvenpaa R, Kellokumpu-Lehtinen PL. No correlation between glucose metabolism and apparent diffusion coefficient in diffuse large B-cell lymphoma: a PET/CT and DW-MRI study. Eur J Radiol 2011; 79: e117-e121. doi:10.1016/j.ejrad.2011.04.062. PMid:21596501.
31. Reischauer C, Froehlich JM, Koh DM, et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion- weighted imaging and functional diffusion maps-initial observations. Radiology 2010; 257: 523-531. doi:10.1148/ radiol.10092469. PMid:20829534.
32. Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol 2011; 196: W790-795. doi:10.2214/AJR.10.5979. PMid:21606271.
33. Takahara T, Kwee T, Kibune S, et al. Whole-body MRI using a sliding table and repositioning surface coil approach. Eur Radiol 2010; 20: 1366-1373. doi:10.1007/s00330-009-1674-1. PMid:19997846.